Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -13.50p -5.24% 244.00p 240.00p 248.00p 257.50p 244.00p 257.50p 55,211 14:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -21.0 -55.7 - 78

ReNeuron Group plc ReNeuron wins Breakthrough of the Year Award

14/06/2019 11:09am

RNS Non-Regulatory


ReNeuron Group plc

14 June 2019

  14 June 2019    AIM: RENE 

RNS Reach

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron wins Breakthrough of the Year Award

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the 'Breakthrough of the Year' award at last night's 2019 European Mediscience Awards in London.

This award underlines the strong clinical development and commercial progress ReNeuron has made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards. We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."

The European Mediscience Awards is one of the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies operating within it.


  ReNeuron                                            +44 (0) 20 3819 8400 
 Olav Hellebø, Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
  Buchanan (UK Media/Investor Relations)              +44 (0) 20 7466 5000 
 Mark Court, Sophie Wills, Tilly Abraham 
  Argot Partners (US Media/Investor Relations) 
   Stephanie Marks, Claudia Styslinger                +1 212 600 1902 
  Stifel Nicolaus Europe Limited (NOMAD and 
   Joint Broker) 
   Jonathan Senior, Stewart Wallace, Ben Maddison     +44 (0) 20 7710 7600 
  N+1 Singer (Joint Broker) 
   Aubrey Powell, Mark Taylor                         +44 (0) 20 7496 3000 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

June 14, 2019 06:09 ET (10:09 GMT)

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190718 17:11:12